Ascendis Pharma A/S filings document foreign private issuer disclosures on Form 6-K, including operating and financial results, clinical and regulatory updates, capital-structure actions and security-structure changes. Recent reports cover TransCon CNP and TransCon hGH data in achondroplasia, the ordinary-share Nasdaq listing that replaced the ADS program, and the exchange of outstanding ADSs into ordinary shares.
The filing record also discloses convertible senior note redemption terms, warrant grants under the company's Articles of Association, registration-statement incorporation by reference, and equity-compensation capacity. Financial disclosures include IFRS reporting items, fair-value and derivative measurements, share capital accounts, treasury shares, and product-related revenue and royalty arrangements.
Ascendis Pharma (ASND) reported a product update via Form 6-K. The company announced commercial availability of SKYTROFA (TransCon hGH) in broader dosing ranges in the United States. The therapy is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.
The report is also incorporated by reference into the company’s effective Form S-8 and Form F-3 registration statements.
Ascendis Pharma (ASND) reported a new employee equity grant. On October 14, 2025, the board granted 31,710 warrants under Appendix 1a of the Articles of Association. Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of $208.71 per share, set at the ADS closing price on the grant date.
The company amended its Articles of Association to provide for this grant. Vesting follows a standard schedule: 25% on the one-year anniversary, then 1/36th monthly for the next three years, subject to continued service and earlier vesting upon certain exit events. After this grant, 1,794,273 warrants remain available for future grants pursuant to the Articles of Association.
Ascendis Pharma A/S reports that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TransCon CNP (navepegritide) as a treatment for children with achondroplasia. Achondroplasia is described as a rare genetic condition that causes skeletal dysplasia and can significantly affect health, physical functioning, and quality of life.
TransCon CNP is an investigational, once-weekly prodrug of C-type natriuretic peptide designed to provide continuous exposure of active CNP throughout the body, including growth plates and skeletal muscle, with the goal of continuously inhibiting the overactive FGFR3 pathway that drives achondroplasia. The filing also notes that this 6-K is incorporated by reference into Ascendis Pharma’s existing Form S-8 and Form F-3 registration statements.
Ascendis Pharma A/S reports that a warrant exercise window for its outstanding warrants closed on September 29, 2025. During this window, certain warrants were exercised for ordinary shares with a nominal value of DKK 1.
As a result, Ascendis registered aggregate share capital increases of nominal DKK 543,748 with the Danish Business Authority, bringing total share capital to nominal DKK 61,695,211 through the issuance of 543,748 ordinary shares. These shares were issued against average cash consideration of approximately USD $97.45 per share, and the company’s articles of association were amended accordingly.
Ascendis Pharma A/S furnished its Articles of Association as an exhibit to the Form 6-K and stated that those articles are to be incorporated by reference into multiple registration statements, specifically a series of S-8 filings and two Form F-3 filings listed in the report. The exhibit is signed by the company’s Executive Vice President, Chief Legal Officer to confirm the submission. This report supplies corporate governance documentation for use in the company’s existing registration statements and related prospectuses.
Form 144 filing for Ascendis Pharma A/S (ASND) shows proposed and recent officer-related sales of American Depositary Shares (ADS). The filing lists a proposed sale of 5,000 ADS through Merrill Lynch on 09/09/2025 with an aggregate market value of $1,018,503.05. The 5,000 ADS were acquired on 09/09/2025 via warrant exercise from Ascendis Pharma A/S and paid for in cash the same day. The filer also reported a sale on 08/13/2025 of 10,000 ADS for gross proceeds of $1,913,224.99. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information about the issuer.
Insider notice of proposed sale under Rule 144 for Ascendis Pharma A/S (ASND). The filing shows 5,000 American Depositary Shares acquired via warrant exercise and to be sold through Merrill Lynch on NASDAQ with an aggregate market value of $965,000. The filer previously sold 9,375 ADS for $1,826,403.05 earlier in August. The filing discloses the acquisition method (warrant exercise), the broker, the number of shares outstanding (60,454,589) and that payment for the exercised ADS was in cash. The signer also represents they have no undisclosed material adverse information about the issuer.
Form 144 notice for Ascendis Pharma A/S (ASND) shows an intended sale of 3,036 American Depositary Shares through Merrill Lynch on NASDAQ with an aggregate market value of $588,814.29 and an approximate sale date of 08/27/2025. The shares were acquired on 09/21/2023 by warrant exercise from Ascendis Pharma A/S for cash. The filing also discloses a separate sale by Lotte Sonderbjerg of 25,000 ADS on 08/14/2025 generating gross proceeds of $4,789,998.27. The filer affirms no undisclosed material adverse information and includes the standard signature and attestation language.
Ascendis Pharma A/S (ASND) filing a Form 144 notifies the market of a proposed sale of 3,000 American Depositary Shares with an aggregate market value of $578,385. The shares represent part of 55,635,376 shares outstanding and are scheduled for sale on 08/20/2025 through Goldman Sachs & Co. LLC. The filer reports acquisition of the 3,000 ADS on 08/20/2025 via warrant exercise and payment in cash. The filing states there were no sales by the filer in the prior three months and includes the standard Rule 144 representation about no undisclosed material adverse information.
Ascendis Pharma A/S (ASND) filed a Form 144 notifying the proposed sale of 9,375 American Depositary Shares on 08/15/2025 through Merrill Lynch on NASDAQ. The filing reports an aggregate market value of $1,826,403.05 and total shares outstanding of 60,454,589. The shares were acquired the same day by warrant exercise from Ascendis Pharma A/S, with cash payment. The filer reports no securities sold in the past three months. The notice includes the standard signature representation that the seller is not aware of any undisclosed material adverse information.